RYTM - Rhythm Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
20.12
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close20.12
Open20.68
Bid0.00 x 1000
Ask0.00 x 800
Day's Range20.08 - 20.82
52 Week Range12.99 - 26.11
Volume204,051
Avg. Volume254,396
Market Cap887.127M
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-3.76
Earnings DateMay 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Rhythm Pharmaceuticals to Present Virtually at Upcoming Investor Conference in June

    Hunter Smith, Interim Chief Executive Officer and Chief Financial Officer, and Murray Stewart, M.D., Chief Medical Officer, will present a corporate overview at 3:00 p.m. ET. Hunter Smith, Interim Chief Executive Officer and Chief Financial Officer, and Murray Stewart, M.D., Chief Medical Officer, will participate in a fireside chat at 3:50 p.m. ET.

  • GlobeNewswire

    Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities

    Rhythm Pharmaceuticals, Inc. (RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for setmelanotide, an investigational, melanocortin-4 receptor (MC4R) agonist, for the treatment of pro-opiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity. The FDA granted Priority Review of the NDA and assigned a Prescription Drug User Fee Act (PDUFA) goal date of November 27, 2020.

  • GlobeNewswire

    Rhythm Pharmaceuticals to Present Virtually at 2020 BofA Securities Health Care Conference

    Rhythm Pharmaceuticals, Inc. (RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Hunter Smith, Interim Chief Executive Officer and Chief Financial Officer of Rhythm, and, Murray Stewart, M.D., Chief Medical Officer of Rhythm, will participate in a fireside chat at the 2020 BofA Securities Health Care Conference on Tuesday, May 12, 2020 at 8:20 a.m. ET. A live audio webcast of the presentation will be available under “Events & Presentations” in the Investor Relations section of the Company’s website at www.rhythmtx.com. Rhythm is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity.

  • GlobeNewswire

    Rhythm Pharmaceuticals Reports First Quarter 2020 Financial Results

    Rhythm Pharmaceuticals, Inc. (RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today reported financial results and provided a business update for the first quarter ended March 31, 2020. “We are excited about the completion of our first New Drug Application (NDA) submission, which marks a critical next step towards bringing a potentially life-changing medicine to individuals living with rare genetic disorders of obesity,” said Hunter Smith, interim Chief Executive Officer and Chief Financial Officer of Rhythm.

  • GlobeNewswire

    Rhythm Pharmaceuticals to Present Virtually at Needham & Co. 19th Annual Healthcare Conference

    BOSTON, April 07, 2020 -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the.

  • GlobeNewswire

    Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities

    Rhythm Pharmaceuticals, Inc. (RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that it has completed its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for setmelanotide for the treatment of pro-opiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity. “The completion of our first NDA submission marks an integral first step in our journey to transform the care of people living with not only POMC and LEPR deficiency obesities, but also many other rare genetic disorders of obesity,” said Murray Stewart, M.D., Chief Medical Officer of Rhythm Pharmaceuticals.

  • GlobeNewswire

    Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

    -- On track to complete rolling NDA submission to the FDA for setmelanotide in POMC and LEPR deficiency obesities in the first quarter of 2020 -- -- Granted orphan drug.

  • Benzinga

    The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering

    The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) ...

  • GlobeNewswire

    Rhythm Pharmaceuticals Announces Leadership Transition

    Rhythm Pharmaceuticals, Inc. (RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., intends to step down as Chief Executive Officer, President and a member of the Company’s Board of Directors. The Board has formed a search committee and retained an executive search firm to assist in identifying Dr. Gottesdiener’s successor.

  • Hedge Funds Are Dumping Rhythm Pharmaceuticals, Inc. (RYTM)
    Insider Monkey

    Hedge Funds Are Dumping Rhythm Pharmaceuticals, Inc. (RYTM)

    At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of September 30. In this […]

  • GlobeNewswire

    Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results

    -- Announced Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities -- -- Added Four New MC4R Pathway.

  • Here’s What Hedge Funds Think About Rhythm Pharmaceuticals, Inc. (RYTM)
    Insider Monkey

    Here’s What Hedge Funds Think About Rhythm Pharmaceuticals, Inc. (RYTM)

    Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and small-cap stocks underperformed the […]

  • Can We See Significant Institutional Ownership On The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Share Register?
    Simply Wall St.

    Can We See Significant Institutional Ownership On The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Share Register?

    If you want to know who really controls Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), then you'll have to look at the...

  • Benzinga

    The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...

  • GlobeNewswire

    Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

    Rhythm Pharmaceuticals, Inc. (RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the pricing of its public offering of 8,108,108 shares of its common stock at a public offering price of $18.50 per share. All of the shares are being offered by Rhythm. In addition, Rhythm has granted the underwriters a 30-day option to purchase up to an additional 1,216,216 shares of common stock at the public offering price, less the underwriting discounts.

  • Benzinga

    The Week Ahead In Biotech: Spotlight On ESMO Conference

    Biotech stocks put up a muted performance in the week ended Sept. 20 amid conference presentations and FDA approvals. Johnson & Johnson (NYSE: JNJ )'s Janssen unit received an FDA nod for label expansion ...

  • GlobeNewswire

    Rhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway-driven Disorders 

    Rhythm Pharmaceuticals, Inc. (RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced plans to expand its Phase 2 Basket Study evaluating setmelanotide to include four additional rare melanocortin-4 receptor (MC4R) pathway-driven disorders. The company will host and webcast a Research & Development (R&D) event to provide an update on genetic sequencing results and the Phase 2 Basket Study on Wednesday, Sept. 25, from 8 to 10 a.m. in New York.

  • Benzinga

    Rhythm Rips Higher After Obesity Drug Aces Late-Stage Trials

    Boston-based Rhythm, which focuses on therapies for rare genetic disorders of obesity, announced positive topline results from two pivotal Phase 3 trials that evaluated its setmelanotide for the treatment of pro-opiomelanocortin, or POMC, and leptin receptor, or LEPR, deficiency obesities. Setmelanotide is Rhythm's melanocortin-4 receptor agonist. The company said both studies met their primary endpoints and all key secondary endpoints, showing a statistically significant and clinically meaningfully effect on weight loss and reductions in insatiable hunger in patients with POMC and LEPR deficiency obesities.

  • GlobeNewswire

    Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities

    Rhythm Pharmaceuticals, Inc. (RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced positive topline results from two pivotal, Phase 3 clinical trials evaluating setmelanotide, the company’s melanocortin-4 receptor (MC4R) agonist, for the treatment of pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesities. Both studies met their primary endpoints and all key secondary endpoints, demonstrating a statistically significant and clinically meaningful effect on weight loss and reductions in insatiable hunger, or hyperphagia, in patients with POMC and LEPR deficiency obesities.

  • GlobeNewswire

    Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results

    -- Launched Uncovering Rare Obesity to facilitate diagnosis of rare genetic disorders of obesity --   -- Announced positive opinion by EMA on Orphan Drug Designation for.

  • GlobeNewswire

    Rhythm Pharmaceuticals Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for Setmelanotide for the Treatment of Bardet-Biedl Syndrome

    Rhythm Pharmaceuticals, Inc. (RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending setmelanotide for designation as an orphan medicinal product for the treatment of patients with Bardet-Biedl syndrome (BBS). People living with BBS may experience an insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life.

  • GlobeNewswire

    Rhythm Pharmaceuticals Launches Free Genetic Testing Program for Rare Genetic Disorders of Obesity

    Rhythm Pharmaceuticals, Inc. (RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the launch of Uncovering Rare Obesity, a free genetic testing program that may help determine if individuals have an underlying genetic cause of their severe obesity. Severe obesity is epidemic in the United States, and Rhythm is focused on identifying people with early-onset obesity that may be caused by certain rare genetic variants.

  • 4 ‘Strong Buy’ Biotechs With Big 3Q19 Catalysts
    TipRanks

    4 ‘Strong Buy’ Biotechs With Big 3Q19 Catalysts

    Investing in biotech stocks can generate substantial returns. If data results meet key targets, or drug applications are accepted, share prices can soar. Unfortunately the reverse is also true. That means investors have to be particularly careful when it comes to biotech stocks. The following four stocks all show a Strong Buy Street consensus- based on ratings received over the last three months. They also boast significant upcoming catalysts this quarter- that could potentially send share prices soaring. Let’s take a closer look at each stock now: 1\. Intercept Pharmaceuticals (ICPT)Intercept Pharma is trying to help patients with progressive non-viral liver diseases. The company already has one drug on the market (for primary biliary cirrhosis), and recently released positive results from the Phase 3 REGENERATE trial in NASH Fibrosis. Nash is a chronic condition in which the buildup of fat and inflammation in the liver may eventually lead to severe scarring called fibrosis. It is currently the second leading cause of liver transplant in the US- making it a very lucrative opportunity for drug companies. Intercept has an early mover advantage here. The company plans to submit an NDA [new drug application] in 3Q19 and an MAA [marketing authorization application] in 4Q19. “Obeticholic Acid will likely be the first to market in NASH and is the only drug to have demonstrated a fibrosis benefit” cheers Needham analyst Alan Carr. “We acknowledge certain potential safety and tolerability limitations, but nevertheless expect the drug to have an important role in NASH therapy over the next several years” says the analyst. Overall the stock has a ‘Strong Buy’ Street consensus, with 5 recent buy ratings vs just 1 hold rating. Meanwhile the average analyst price target of $148 indicates huge upside potential of 113%. >>Click Here to see the full list of ICPT Analyst Ratings 2\. Rhythm Pharmaceuticals (RYTM)Rhythm is developing treatments for rare genetic deficiencies that result in life-threatening metabolic disorders. The big news here is that Rhythm is expected to announce results in 3Q19 from two Phase 3 trials of setmelanotide in POMC and LEPR Deficiency. There are currently no approved drugs for these diseases- and no other drugs in development.“We anticipate a positive outcome for both trials based on Phase 2 data demonstrating a profound and durable impact on appetite and weight” writes Carr. The analyst assumes US approval and launch in 4Q20 (EU 2021) and peak worldwide sales of around $265M in 2032.“Considering recent weakness, we believe the stock is attractive ahead of Phase 3 POMC and LEPR Deficiency trial results. We believe there is even more room for upside for the stock as the company completes label expansion trials in 2020+” enthuses Carr. Most notably label expansion Phase 3 trial in Bardet-Biedl/Alstrom Syndromes remains on track for results in 2H20. Success here adds another $485M in peak sales potential. “Additional patient populations under evaluation in a Phase 2 trial push peak sales above $1B” writes Carr. RYTM has four consecutive recent buy ratings from the Street, with an average price target of $40 (95% upside potential). >>Click Here to see the full list of RYTM Analyst Ratings 3\. Moderna Inc (MRNA)Moderna is hoping to create a new generation of transformative medicines for patients. The company’s approach is to use mRNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease. Encouragingly, all seven analysts covering MRNA rate the stock a buy- so no hold or sell ratings here. “We expect Moderna to provide updates on Cytomegalovirus (CMV), Chikungunya, and Methylmalonic Acidemia (MMA) programs by YE19” writes the analyst.While the commercial opportunity in Chikungunya is modest, he believes PK/PD data from the Phase 1 trial will provide valuable insight into the overall predictability of several other mRNA drugs in development at the company.“The stock has fallen substantially from its peak in May 2019. We believe there is an opportunity for upside in 2H19 as the company announces data from the above CMV, Chikungunya, and MMA programs” Carr concludes. Indeed, the Street’s $30 average price target suggests share prices can double in the coming months. >>Click Here to see the full list of MRNA Analyst Ratings 4\. Cara Therapeutics (CARA)Cara Therapeutics has surged 30% in last the three months. In May the company announced positive results from the first of two Phase 3 trials of IV Korsuva in Chronic Kidney Disease (CKD) dialysis patients with pruritus. Pruritus refers to the severe itching of the skin, a common and distressing symptom for patients with chronic kidney disease. Cara Therapeutics CEO Derek Chalmers noted at the time that the company was "particularly encouraged by the early [anti-itching] response with Korsuva injection." Now investors are keeping a close eye on results from the second trial (KALM-2) and from a Phase 2 trial of oral Korsuva in non-dialysis patients with CKD pruritus- both expected in 2H19. “We anticipate a positive outcome for both trials” comments Carr, adding that the recent results point to a favorable outcome for the KALM-2 trial. “We believe the outcome is also a positive indicator for the oral Korsuva programs in CKD pruritus, Liver Disease pruritus, and Atopic Dermatitis, all of which have large commercial opportunities.”Bottom line: “The stock is substantially undervalued.” All six analysts polled are bullish on CARA right now. Meanwhile the average analyst price target stands at $33 (30% upside potential). >>Click Here to see the full list of CARA Analyst RatingsDiscover the latest ratings from top analysts in any sector you choose

  • GlobeNewswire

    Rhythm Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference

    BOSTON, May 30, 2019 -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the.